Drugs / CM355
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05210868 | Nov 2021 → Dec 2026 expected | — | Beijing InnoCare Pharma Tech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07104344 | Sep 2025 → Apr 2026 overdue | systemic lupus erythematosus | Second Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-06-14 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 诺诚健华多项肿瘤管线数据在2024年欧洲血液学协会年会上公布 innocarepharma.com ↗
结果显示，总缓解率（ORR）为100.0%，其中完全缓解率（CRR）为77.8%。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-14 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华多项肿瘤管线数据在2024年欧洲血液学协会年会上公布 innocarepharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM355 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05210868 ↗ |